Two key developments in US oncology signal faster progress: a new standard therapy for aggressive colorectal cancer and …
Two key developments in US oncology signal faster progress: a new standard therapy for aggressive colorectal cancer and …
Prime Minister Starmer unveils ambitious reforms to speed up trial timelines and centralize NHS data, aiming to restore …
An investigational RNA-based therapy shows significant reduction in disease-causing protein levels—potentially a meaningful step forward in treating Huntington’s …
Vera Therapeutics completed full enrolment in its pivotal trial of atacicept in IgA nephropathy and Minovia Therapeutics received …
In a shareholder letter released on 1 April 2025, MAIA Biotechnology revealed plans to advance telomere‐targeted therapies in …
Experimental gene-silencing drug lepodisiran delivers long-lasting reduction of cardiovascular risk factor, while Spinogenix launches trial for novel synaptic …
Viking Therapeutics and Bluejay Therapeutics highlight progress in obesity management and neurological disease treatment with key clinical milestones.
Merck’s global license deal for HRS-5346 and Tiziana’s intranasal foralumab Phase 2 trial signify strides in cardiovascular and …
Abbott receives FDA approval to begin Phase 3 trial of its Intravascular Lithotripsy system aimed at improving outcomes …
Positive safety and efficacy review by independent board positions MaaT013 as Europe’s potential first-approved microbiome-based drug for severe …
Already a subscriber? Log in